Experimental design of bioassays for screening and low dose extrapolation
- PMID: 3843676
- DOI: 10.1111/j.1539-6924.1985.tb00147.x
Experimental design of bioassays for screening and low dose extrapolation
Abstract
Relatively high doses of chemicals generally are employed in animal bioassays to detect potential carcinogens with relatively small numbers of animals. The problem investigated here is the development of experimental designs which are effective for high to low dose extrapolation for tumor incidence as well as for screening (detecting) carcinogens. Several experimental designs are compared over a wide range of different dose response curves. Linear extrapolation is used below the experimental data range to establish an upper bound on carcinogenic risk at low doses. The goal is to find experimental designs which minimize the upper bound on low dose risk estimates (i.e., maximize the allowable dose for a given level of risk). The maximum tolerated dose (MTD) is employed for screening purposes. Among the designs investigated, experiments with doses at the MTD, 1/2 MTD, 1/4 MTD, and controls generally provide relatively good data for low dose extrapolation with relatively good power for detecting carcinogens. For this design, equal numbers of animals per dose level perform as well as unequal allocations.
Similar articles
-
Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?Regul Toxicol Pharmacol. 2005 Mar;41(2):128-33. doi: 10.1016/j.yrtph.2004.11.001. Epub 2004 Dec 19. Regul Toxicol Pharmacol. 2005. PMID: 15698536
-
Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose.Regul Toxicol Pharmacol. 1998 Dec;28(3):222-5. doi: 10.1006/rtph.1998.1258. Regul Toxicol Pharmacol. 1998. PMID: 10049793
-
Optimal design of the chronic animal bioassay.J Toxicol Environ Health. 1983 Jul;12(1):1-19. doi: 10.1080/15287398309530403. J Toxicol Environ Health. 1983. PMID: 6631999
-
An appreciation of the maximum tolerated dose: an inadequately precise decision point in designing a carcinogenesis bioassay?Teratog Carcinog Mutagen. 1991;11(6):279-96. doi: 10.1002/tcm.1770110602. Teratog Carcinog Mutagen. 1991. PMID: 1687837 Review.
-
Epidemiological and experimental applications to occupational cancer prevention.J UOEH. 1989 Mar 20;11 Suppl:323-45. J UOEH. 1989. PMID: 2664947 Review.
Cited by
-
Biological bases for cancer dose-response extrapolation procedures.Environ Health Perspect. 1991 Jan;90:293-6. doi: 10.1289/ehp.90-1519475. Environ Health Perspect. 1991. PMID: 2050075 Free PMC article.
-
How subchronic and chronic health effects can be neglected for GMOs, pesticides or chemicals.Int J Biol Sci. 2009 Jun 17;5(5):438-43. doi: 10.7150/ijbs.5.438. Int J Biol Sci. 2009. PMID: 19584953 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources